Prometheus Biosciences Announces Results For PRA023 In Both ARTEMIS-UC Phase 2 And APOLLO-CD Phase 2a Studies; ARTEMIS-UC Met Primary Endpoint
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and